anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

Source Note

Component collection for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Matching slides 110,355
Current window 66,901-66,930
Pages 3,679
Rows per page 30
Component: Source Noteclear collectionreset all
18 30 60

Component

66,901-66,930 of 110,355

filter-aware
18
Study uses male DIO-NASH mice with 30-week GAND feeding and 9-week treatment regimen.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
19
Includes study methodology timeline and statistical significance markers.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
20
NASH (Non-Alcoholic Steatohepatitis); MAD (Multiple Ascending Dose); SAD (Single Ascending Dose); PK (Pharmacokinetic); PD (Pharmacodynamic); FPFV (First Patient First Visit); LPLV (Last Patient Last Visit).NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · SolutionLoop · Quick Win Big Bet1 hit
24
The slide highlights rapid adoption compared to Saxenda and notes supply chain issues impacting Q4'21 and H1'22.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
25
The slide uses a 'before-after' style comparison to show the potential market cap uplift for NeuroBo's assets compared to current peer valuations.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
26
Includes footnotes regarding anti-dilution provisions and Dong-A license agreement terms.NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations Beat · Financials1 hit
27
NeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slidesNeuroBo Pharmaceuticals | Securities Offering Presentation Deck | 30 slides · NeuroBo Pharmaceuticals
Regulatory filing Investor relations 1 hit
04
Includes a molecular visualization of the inhibitor binding to the protein.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
05
The slide uses a matrix-like structure to compare drug capabilities against specific clinical requirements.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
06
The slide uses a human anatomy diagram to map specific TRK receptor inhibition (TRKB, TRKC, TRKA) to associated clinical side effects.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Beat · ProblemLoop · Cost Of Inaction1 hit
08
The slide uses dot plots for IC50 values and a bar chart for tumor regression, highlighting NVL-520's performance.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
12
The slide uses a process-flow style diagram to show how initial cohorts are expanded via back-filling and then filtered into a response-evaluable population.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
13
The slide presents baseline patient characteristics and prior treatment history for a clinical trial cohort.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
19
Includes a spider plot (waterfall-like over time) and a bar chart showing allele clearance.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
22
Slide 22 of a conference presentation.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
27
The slide compares vehicle control vs NVL-655 treatment across multiple cell lines and a patient-derived xenograft (PDX) model.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
30
The slide uses three distinct chart types to demonstrate drug efficacy and safety profile.Nuvalent | Investor Presentation Deck | 31 slides · Nuvalent
Conference presentation Investor relations 1 hit
10
Includes a scientific diagram illustrating the biogenesis of EVs (exosomes, microvesicles, apoptotic bodies).Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations Loop · Voice Of Customer1 hit
11
The slide uses two scientific diagrams to illustrate the biological mechanism and molecular content of exosomes.Organicell Regenerative Medicine | Investor Presentation Deck | 17 slides · Organicell Regenerative Medicine
Pitch deck Investor relations 1 hit
05
The slide uses a combination of absolute revenue growth and YoY percentage trends to demonstrate business stabilization.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Need1 hit
12
The chart uses a combination of bar (absolute $) and line (percentage) to show trends.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
15
The chart displays a decline in order volume alongside an increase in average order value.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
16
The slide uses a before-after framing to isolate the impact of 'non-home only' customers on overall performance metrics.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
17
The slide uses a clear layout to contrast balance sheet status with specific capital allocation activities.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide highlights Overstock's position as a top 4 player in a large, growing market.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · VisualizationLoop · David Goliath1 hit
20
The slide uses a 2x2 matrix to highlight Overstock's unique positioning in the 'Value' quadrant.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations Beat · VisualizationLoop · David Goliath1 hit
34
The table reconciles GAAP Diluted EPS to an Adjusted Diluted EPS figure by adjusting for equity method income/loss.Overstock | Results Presentation Deck | 34 slides · Overstock
Conference presentation Investor relations 1 hit
04
The slide uses a simple flow diagram to illustrate the business model components.Pathward Financial | Results Presentation Deck | 25 slides · Pathward Financial
Conference presentation Investor relations Beat · Interest1 hit
06
The charts highlight adjusted earnings for 2022 compared to GAAP earnings.Pathward Financial | Results Presentation Deck | 25 slides · Pathward Financial
Conference presentation Investor relations Beat · Desire1 hit
07
The slide uses a combination of big numbers for cumulative totals and an area chart to show the reduction in share count over time.Pathward Financial | Results Presentation Deck | 25 slides · Pathward Financial
Conference presentation Investor relations Beat · Desire1 hit